Overview

An area of research we are exploring is growing new blood vessels to treat PAD patients with our drug candidate CVBT-141C. Pre-clinical trials have shown that CVBT-141C may improve blood supply to the legs and feet to decrease pain and prevent tissue loss. Animal efficacy studies with our drug candidate in a rabbit model of PAD demonstrated that it increased iliac artery blood flow, collateral vessel density and microvascular development in the legs of the treated animals.

The FDA has reviewed the protocol for a Phase I clinical study in PAD patients and has allowed the clinical trial to proceed.

Enrollment

We have not yet begun enrollment for our Phase I PAD trial. Please check back for updates.

Trial Locations

The list of trial locations is not currently available. If you would like to receive an email alert when enrollment opens for our PAD trial, please complete our Clinical Trial Inquiry Form.

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2010 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.